07:54 AM EDT, 09/29/2025 (MT Newswires) -- Dogwood Therapeutics ( DWTX ) shares surged 64% in Monday's premarket session after it said it acquired a royalty-free, global license from Serpin Pharma to develop Serpin's SP16 to manage cancer-related pain.

Under the terms of the deal, Serpin Pharma and its designated affiliates will receive 382,034 shares of Dogwood Therapeutics ( DWTX ) common stock and 179.1878 shares of a new series of non-voting convertible preferred stock, which amounts to 7.31% of Dogwood's common stock, the company said.